UBS analyst Ashwani Verma initiated coverage of Exelixis with a Neutral rating and $30 price target. The firm expects the company’s Cabometyx growth to slow down to mid-single digit year-over-year trends in 2024 and 2025 while the drug faces potential intellectual property risk from 2026 onwards. The slow Cabo growth and gradual pipeline diversification are priced into the stock, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis put volume heavy and directionally bearish
- Exelixis CABINET data support potential label expansion, says Citi
- Exelixis announces final results from CABINET study
- Exelixis presents final overall survival results from Phase 3 CONTACT-02 study
- Exelixis call volume above normal and directionally bullish